Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

Data by

Global Data

4

Revenue 2014

Sanofi

The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Sanofi's 2013 sales performance.

Repatha outcomes data "less than stellar"

Repatha outcomes data "less than stellar"

It is one of only two PCSK9 inhibitors on the market, along with Sanofi and Regeneron's Praluent (alirocumab) which is also experiencing slow-take up and made 104m ($112m) in ... Sanofi and Regeneron are waiting for the results of their own

NICE backtracks on Biogen's multiple sclerosis drug Zinbryta

NICE backtracks on Biogen's multiple sclerosis drug Zinbryta the disease if they have failed to respond to first-line treatment with Sanofi's Lemtrada (alemtuzumab) or have rapidly evolving severe MS.

Sanofi to develop a mobile app for insulin patients

Sanofi to develop a mobile app for insulin patients Sanofi to develop a mobile app for insulin patients. Will work with therapeutic companion software company Voluntis. ... Peter Guenter, executive vice-president, diabetes and cardiovascular at Sanofi, said: "Sanofi is focusing on a beyond-the-pill

Cello Health Consulting expands its UK team

Cello Health Consulting expands its UK team Tarplee has over 30 years of life science industry experience and previously worked for the likes of Adherium, ALK Abello, Sanofi and Abbott. ... Lim previously worked at Novartis and Sanofi Pasteur, and most recently served at Takeda Pharmaceuticals as

Amicus Therapeutics launches Fabry treatment Galafold in Italy

Amicus Therapeutics launches Fabry treatment Galafold in Italy Galafold is the first orally administered alternative to the current crop of injectable enzyme replacement therapies (ERT) for Fabry disease, such as Sanofi's Fabrazyme (agalsidase beta).

Result pages: 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 ()

Sanofi
Global revenue 2014
1: Novartis
2: Pfizer
3: Roche
4: Sanofi
5: Merck & Co.
6: Johnson & Johnson
7: GlaxoSmithKline
8: AstraZeneca
9: Gilead Sciences
10: Takeda
11: AbbVie
12: Amgen
13: Teva
14: Lilly
15: Bristol-Myers Squibb
16: Bayer
17: Novo Nordisk
18: Astellas
19: Boehringer Ingelheim
20: Actavis
21: Otsuka
22: Daiichi Sankyo
23: Biogen Idec
24: Baxter
25: Merck KGaA
US revenue 2014
1: Gilead Sciences
2: Johnson & Johnson
3: Pfizer
4: Roche
5: Novartis
6: Amgen
7: Merck & Co.
8: Sanofi
9: AbbVie
10: Actavis
11: AstraZeneca
12: GlaxoSmithKline
13: Lilly
14: Bristol-Myers Squibb
15: Novo Nordisk
Oncology revenue 2014
1: Roche
2: Novartis
3: Celgene
4: Johnson & Johnson
5: Bristol-Myers Squibb
6: Lilly
7: Takeda
8: AstraZeneca
9: Merck & Co.
10: Amgen
11: Pfizer
12: Astellas
13: Bayer
14: Otsuka
15: Sanofi
16: Merck KGaA
17: Eisai
18: AbbVie
19: Pharmacyclics
20: Incyte
CNS revenue 2014
1: Pfizer
2: Biogen Idec
3: Novartis
4: Otsuka
5: Teva
6: Johnson & Johnson
7: Lilly
8: Merck KGaA
9: AstraZeneca
10: Shire
11: Bristol-Myers Squibb
12: UCB
13: Lundbeck
14: Eisai
15: GlaxoSmithKline
16: Sanofi
17: Mylan
18: Indivior
19: Actavis
20: Bayer
Cardiovascular revenue 2014
1: AstraZeneca
2: Sanofi
3: Merck & Co.
4: Daiichi Sankyo
5: Pfizer
6: Novartis
7: Bayer
8: Takeda
9: Boehringer Ingelheim
10: Astellas
11: Actelion
12: Johnson & Johnson
13: Shionogi
14: United Therapeutics
15: Bristol-Myers Squibb
16: Gilead Sciences
17: Otsuka
18: Roche
19: Lilly
20: The Medicines Company
Metabolic revenue 2014
1: Novo Nordisk
2: Sanofi
3: Merck & Co.
4: Lilly
5: AstraZeneca
6: Takeda
7: Novartis
8: Amgen
9: Bayer
10: Merck KGaA
11: Salix Pharmaceuticals
12: AbbVie
13: Dainippon Sumitomo Pharma
14: Kyowa Hakko Kirin
15: Mitsubishi Tanabe
Biologic revenue 2014
1: Roche
2: Amgen
3: Novo Nordisk
4: AbbVie
5: Sanofi
6: Johnson & Johnson
7: Pfizer
8: Merck & Co.
9: Lilly
10: Biogen Idec
11: Merck KGaA
12: GlaxoSmithKline
13: Bristol-Myers Squibb
14: Novartis
15: Bayer

Global Data Data by GlobalData

GlobalData is the premier source of research and consulting solutions for the pharmaceutical and medical device industries. With the combined expertise of more than 600 researchers, market analysts and consultants, we deliver high-quality, accurate and transparent industry insight that helps our clients to achieve growth and increase business value.

To find out more about how our research and consulting solutions can help you, please visit healthcare.globaldata.com

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
eyeforpharma

eyeforpharma is a hub for senior-level pharma executives, patient advocacy groups and other health experts to exchange ideas and stay...

Latest intelligence

Precision medicine and the changing role of the healthcare professional
The growth of precision medicine introduces a shift away from treating the population as a whole, to treating each patient as an individual. How does this change the role of...
How will Sustainability and Transformation Plans (STPs) change the NHS commissioning landscape?
Sue Thomas and Paul Midgley, of Wilmington Healthcare, take a look at new commissioning structures and what they mean for pharma...
eyeforpharma Barcelona 2017 highlights: Industry at the brink of transformation
Hear what Anthill's delegates reported back from the biggest eyeforpharma Barcelona yet....

Infographics